Experts Call for Doctor-Style Licensure of Autonomous Clinical AI

Historically, healthcare AI regulation has followed the medical device paradigm established by the Safe Medical Devices Act and subsequent FDA guidance. This framework evaluates software based on intended use, risk classification, and substantial equivalence to predicate devices. Previous debates regarding AI in medicine focused on algorithmic transparency, bias mitigation, and post-market surveillance within this device-centric model. The concept of licensing non-human entities parallels discussions in aviation (autonomous flight systems) and law (electronic personhood), where functional capacity triggers regulatory status independent of manufacturer identity. Prior attempts to modernize AI regulation, such as the Predetermined Change Control Plan, sought to accommodate adaptive algorithms while retaining the device classification structure. The current proposal diverges from this lineage by decoupling regulatory status from manufacturing and anchoring it instead in clinical privilege and scope of practice, a domain traditionally reserved for natural persons and corporate entities holding institutional licenses.

On April 29, 2026, Alon Bergman, Robert Wachter, and Ezekiel Emanuel published a Perspective in JAMA proposing a formal licensure framework for autonomous clinical AI systems. The authors argue that the current regulatory paradigm, which treats AI primarily as medical devices under FDA oversight, is insufficient for systems capable of independent clinical decision-making and patient care actions. According to the proposal outlined in JAMA and subsequent summaries by Penn LDI and STAT News, the authors advocate adapting the physician licensure model to create a standardized credentialing system specifically for autonomous AI agents.

The proposed framework consists of six core components designed to mirror medical training and board certification. As described by Matt Pavelle on LinkedIn and confirmed by HealthExec, these include standardized competency assessments, supervised practice periods, defined scopes of practice, and ongoing performance monitoring. The authors contend that because autonomous AI differs fundamentally from traditional software-as-a-medical-device (SaMD), it requires governance structures that evaluate continuous clinical reasoning rather than static technical specifications. Zeke Emanuel and Robert Wachter are cited in multiple sources as emphasizing that these models will increasingly take direct actions in patient care, necessitating a shift from device approval to practitioner-style accountability.

The publication triggered immediate discourse regarding the feasibility of applying human-centric professional standards to non-sentient software. Supporters, including commentators on LinkedIn, characterized the proposal as a necessary evolution for safety, arguing that existing regulations fail to address the unique risks of autonomy. Conversely, the proposal implicitly critiques the FDA's current jurisdictional approach, suggesting that without legislative or regulatory expansion, autonomous systems may operate in a liability gray zone. While the FDA has not issued a formal response to this specific JAMA article within the provided timeline, the authors' call likely targets future policy formulation rather than immediate agency enforcement.

This controversy represents a conceptual pivot point in health AI governance: moving from product regulation to entity licensure. The authors assert that just as physicians must demonstrate competence before practicing independently, autonomous AI should undergo similar validation. The proposal does not allege specific malfeasance by current regulators but identifies a structural gap where technology has outpaced the legal definitions of medical practice. As noted by Penn LDI, the work was published as part of a broader effort to regulate AI without stifling innovation, positioning licensure as an enabler of trust rather than merely a barrier to entry.

The narrative remains focused on the theoretical architecture of this framework. No pilot programs have been mandated, and no state medical boards have adopted the Bergman-Wachter-Emanuel model as of the latest available dates. However, the involvement of high-profile figures like Emanuel and Wachter lends significant weight to the argument, ensuring that the concept of 'AI licensure' enters the mainstream policy lexicon distinct from standard FDA clearance pathways. The debate now centers on whether such a framework can be operationalized without creating insurmountable barriers for developers or conflicting with federal preemption doctrines governing medical devices.

Primary stakeholders include autonomous AI developers who may face dual regulatory tracks (FDA plus licensure), increasing time-to-market and compliance overhead. Healthcare systems deploying these tools could encounter new credentialing liabilities analogous to hospital privileging. Patients are the intended beneficiaries through standardized competency verification, though access to advanced AI could contract if barriers become prohibitive. The magnitude is currently speculative as no legislation exists, but successful adoption would represent the most significant restructuring of health AI governance since the 21st Century Cures Act. Liability insurers would need to develop new actuarial models for licensed non-human practitioners.